In re Opana Antitrust Litig., No. 14-10150 (N.D. Ill.)
In re Opana Antitrust Litig., No. 14-10150 (N.D. Ill.)
In the Opana case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Endo Pharmaceuticals’ Oxymorphone ER, sold under the brand name Opana ER. The proposed class alleges that Endo and would-be generic competitor Impax Laboratories entered an illegal reverse payment agreement under which Endo paid Impax more than $100 million to delay launching a less-expensive generic version of Opana ER.
Details
Counsel
Joseph T. Lukens
jlukens@faruqilaw.com
Phone (215) 277-5770
Fax (215) 277-5771
Peter Kohn
pkohn@faruqilaw.com
Phone (215) 277-5770
Fax (215) 277-5771
Office
New York
685 Third Avenue 26th Floor
New York New York 10017
Phone (212) 983-9330
Fax (212) 983-9331
